RxDoctor Payments Data

David Albright, MD

Family Medicine · Ocala, FLNPI 1952463846

Payments from drug & device makers

$672in general payments, 2019–2025

Across 14 payments — averaging $47.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$309
  • GSK$273
  • Amgen$31
  • Pfizer$21
  • Lilly USA, LLC$21
  • Novo Nordisk$17

What the payments were for

  • Food & beverage$672100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca3$309
GSK6$273
Amgen2$31
Pfizer1$21
Lilly USA, LLC1$21
Novo Nordisk1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$672 in reported general payments places this provider in the 55th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$358,875
Medicare patients
424
Services billed
12,142

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban118$133,101
FarxigaDapagliflozin Propanediol32$45,140
JardianceEmpagliflozin33$36,327
OzempicSemaglutide22$31,448
TrulicityDulaglutide21$29,239
MounjaroTirzepatide20$19,568
XareltoRivaroxaban14$18,756
JanuviaSitagliptin Phosphate17$14,200
MyrbetriqMirabegron17$12,036
Stiolto RespimatTiotropium Br/Olodaterol Hcl13$6,669
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$3,937
Levothyroxine Sodium345$3,805
Atorvastatin Calcium338$3,276
Pravastatin Sodium223$2,604
SynthroidLevothyroxine Sodium30$2,436

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$21$133,101118 claims
Lilly USA, LLCTrulicity, Mounjaro$21$48,80841 claims
AstraZenecaFarxiga$309$45,14032 claims
Novo NordiskOzempic$17$31,44822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Ocala

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →